Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 20%Low 3 · 60%Moderate 1 · 20%High 0 · 0%

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Weight gain · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Specific ‐ weight increase compared with ORAL ARIPIPRAZOLE (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.57 [0.38, 6.45]
1 study · 374 participants
Low

RISPERIDONE DEPOT vs OLANZAPINE

Weight gain · patients with schizophrenia

RISPERIDONE DEPOT may leads to lower adverse events: Specific ‐ weight increase compared with ORAL OLANZAPINE (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.56 [0.42, 0.75]
1 study · 547 participants
Low

RISPERIDONE DEPOT vs QUETIAPINE

Adverse events: Specific: Mean (SD) weight increase in kg ‐ long term · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 666 participants
Low

RISPERIDONE DEPOT vs RISPERIDONE

Weight gain · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 640 participants
Moderate

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Weight gain · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ weight increase ‐ long term It is unclear… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.33 [0.56, 3.17]
1 study · 85 participants
Very low